Table 3. Association of CXCL17 with clinicopathological characteristics.

		Nontumoral CXCL17			Peritumoral CXCL17			Intratumoral CXCL17
Variable		Low	High	P	Low	High	P	Low	High	P
Age (year)	≤51	58	58	0.946	62	54	0.320	60	56	0.549
	>51	56	55		52	59		53	58
Gender	Male	99	98	0.979	100	97	0.676	98	99	0.979
	Female	15	15		14	16		15	15
HBsAg	Negtive	8	10	0.610	9	9	0.984	9	9	0.984
	Positive	106	103		105	104		104	105
Cirrhosis	Absent	47	38	0.237	50	35	0.045	49	36	0.067
	Present	67	75		64	78		64	78
ALT (U/liter)	≤42	67	71	0.531	68	70	0.723	70	68	0.723
	>42	47	42		46	43		43	46
AST (U/liter)	≤42	62	69	0.309	60	71	0.120	64	67	0.745
	>42	52	44		54	42		49	47
AFP (ng/ml)	≤25	38	40	0.743	35	43	0.244	33	45	0.103
	>25	76	73		79	70		80	69
Tumor size (cm)	≤5	51	45	0.454	48	48	0.955	49	47	0.745
	>5	63	68		66	65		64	67
Tumor differentiation	I + II	58	71	0.069	54	75	0.004	63	66	0.745
	III + IV	56	42		60	38		50	48
Vascular invasion	Absent	93	93	0.888	95	91	0.583	95	91	0.406
	Present	21	20		19	22		18	23
Tumor multiplicity	Solitary	83	87	0.467	83	87	0.467	84	86	0.848
	Multiple	31	26		31	26		29	28
Capsulation	Absent	23	29	0.325	21	31	0.106	23	29	0.362
	Present	91	84		93	82		90	85
TNM stage	I + II	67	55	0.127	68	54	0.073	66	56	0.161
	III + IV	47	58		46	59		47	58
BCLC stage	0–A	68	68	0.935	69	67	0.850	69	67	0.725
	B–C	46	45		45	46		44	47

Note: Underlined terms indicate statistical significance. Abbreviations: AFP: alpha-fetoprotein; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BCLC: Barcelona Clinic Liver Cancer; CI: confidence interval; HBsAg: hepatitis B surface antigen; TNM: tumor-nodes-metastasis.